Galectin Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GALT | FULC | FTH | NBP | UPB | KROS | |
|---|---|---|---|---|---|---|
| Market cap | 349.95M | 287.96M | 516.62M | 117.16M | 202.65M | 214.73M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.1 | -6.9 | -5.4 | -0.8 | -1.3 | -1.6 |
| Price/book | -1.7 | 0.9 | 1.4 | 0.6 | 0.7 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −37.81% | −52.48% | +121.53% | −76.29% | −85.86% | −30.80% |
| Today | +3.58% | +0.80% | +1.73% | 0.00% | +9.14% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GALT news ›Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.29 and traded as high as $3.84. Galectin…
[ARS] GALECTIN THERAPEUTICS INC SEC Filing
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company developing galectin-3-targeted drug belapectin for MASH cirrhosis and cancer. [ARS] GALECTIN THERAPEUTICS INC SEC Filing Sentiment and the balance of points…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketbeat.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.